芪苈强心胶囊治疗慢性心力衰竭系统评价的再评价

[目的]对芪苈强心胶囊治疗慢性心力衰竭的系统评价进行方法学质量和结局指标证据级别的评价。[方法]检索中文全文期刊数据库(CNKI)、万方数据库(Wanfang Data)、中国生物医学文献数据库(SinoMed、PubMed)、The Cochrane Library和Embase数据库,收集芪苈强心胶囊治疗慢性心力衰竭的系统评价,检索日期为建库至2019年4月。由两名研究者独立提取资料并根据AMSTAR2评分量表及GRADE评价体系对所纳入系统评价的方法学质量和结局指标证据级别进行评价。[结果]研究共纳入15篇系统评价。AMSTAR 2方法学质量评价结果显示,全部系统评价均为低质量。GRADE证据级别评价结果显示:15篇系统评价包含12个结局指标,共64个证据个体。其中有1个高等质量(占比1.6%),9个中等质量(占比14%),25个低等质量(占比39%),29个极低等质量(占比45.3%)。[结论]芪苈强心胶囊治疗慢性心力衰竭具有良好的疗效,系统评价的方法学质量较低,证据级别总体较低。建议系统评价应按照严格的程序进行研究,规范报告研究结果。

Qili Qiangxin Capsule for treatment of chronic heart failure:an overview of systematic reviews

[Objective] To evaluate the methodological quality and evidence level of outcomes about systematic review of Qili Qiangxin Capsule for chronic cardiac failure.[Methods] CNKI,Wanfang Data,SinoMed,PubMed,The Cochrane Library and Embase databases were researched to collect the systematic reviews of Qili Qiangxin Capsule for chronic heart failure. Date were retrieved from the inception of databases until April,2019. Two investigator screened literature independently and extracted data,and the methodological quality of systematic reviews were evaluated by AMSTAR2 scale,quality of evidence was graded by the GRADE system.[Results] A total of 15 systematic reviews were included. AMSTAR2 methodological quality evaluation results show that all systematic evaluation are low quality or very low quality. The results of GRADE evidence level evaluation showed that 15 systematic reviews included 12 outcomes,64 evidences. There were 1 high quality (1.6% of the total quantity),9 medium quality (14%),25 low quality (39%) and 29 very low quality (45.3%).[Conclusion] Qili Qiangxin Capsule in the treatment of chronic heart failure has good efficacy and safety,but the methodological quality and evidence level of systematic is low,and it is suggested that systematic review should be designed in a more rigorous and scientific way.